Tiragolumab (TIGIT/VSIG9/VSTM3) Antibody, Monoclonal | 10-856

Tiragolumab (TIGIT/VSIG9/VSTM3) Antibody, Monoclonal | 10-856 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Homo sapiens / TIGIT/VSIG9/VSTM3 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: MTIG-7192-A, MTIG-7192A, MTIG7192A, RG-6058, RO-7092284, RO7092284

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Tiragolumab is fully humanized monoclonal antibody. Tiragolumab targets TIGIT and directly or indirectly activates anti-tumor immune responses by acting on the activation pathways of APC and T cells and NK cells to achieve the purpose of eliminating tumor cells.